Clinical Trial Update: A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550 [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study in healthy subjects comparing absorption of CP-690,550 from two different strength tablets; Pfizer-sponsored.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Xeljanz (tofacitinib) (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Phase 1 | Status: COMPLETED